Research & Hope Awards

Washington, D.C. (September 11, 2013) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today the recipients of the 2013 Research & Hope Awards, honoring outstanding achievements in vaccines research and immunization by individuals and research teams in the biopharmaceutical sector, academic/public research and health care provider communities.

Medicines in Development: Vaccines

WASHINGTON, D.C. (September 11, 2013) – America’s biopharmaceutical companies are currently developing 271 vaccines to prevent – and in some cases treat – a variety of conditions, including infectious diseases, various forms of cancer and neurological disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

2013 Research and Hope Award bios

Linda Fu, MD, MScChildren’s National Medical Center Vaccine Program, under the guidance of Linda Yu-Sing Fu, MD, MSc

2013 Research and Hope Award bios

Douglas Lowy, MDDouglas Lowy, MD
Deputy Director
National Cancer Institute

2013 Research and Hope Award bios

Dr. Sophie BiernauxDr. Sophie Biernaux serves as Head of the Malaria Vaccine Franchise for GlaxoSmithKline Biologicals where she leads the company’s research and development efforts on malaria vaccines. Dr. Biernaux currently directs all aspects of GSK’s work in advancing the RTS,S malaria vaccine candidate, including the management of the Phase IIIs trial across Africa in conjunction with the company’s Global R&D Department.

Medicines in Development for Vaccines

PhRMA Vaccine Fact Book 2013

Docket No. FDA-2013-D-0575: Draft Guidance for Industry on Expedited Programs for Serious Conditions—Drugs and Biologics; Availability; 78 Fed. Reg. 38349 (June 26, 2013)

Research in South Carolina

Clinical Trials: Neurological Disorders

There are more than 2,000 clinical trials listed in the National Institutes of Health database – www.clinicaltrials.gov – for neurological disorders, such as Alzheimer’s disease, brain tumors, chronic pain, epilepsy, headache, multiple sclerosis and Parkinson’s disease.  Of those trials, more than 350 are either recruiting patients or have not yet started recruiting patients.  This information is potentially valuable to patients still seeking effective treatments for one of the many neurological disorders.  It provides a new therapeutic option to

Pages

Subscribe to RSS - Innovation